Cargando…

Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer From SOLAR-1

In the phase III SOLAR-1 trial (NCT02437318), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)–mutated, hormone recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ciruelos, Eva Maria, Rugo, Hope S., Mayer, Ingrid A., Levy, Christelle, Forget, Frédéric, Delgado Mingorance, Juan Ignacio, Safra, Tamar, Masuda, Norikazu, Park, Yeon Hee, Juric, Dejan, Conte, Pierfranco, Campone, Mario, Loibl, Sibylle, Iwata, Hiroji, Zhou, Xiaolei, Park, Jinhee, Ridolfi, Antonia, Lorenzo, Ines, André, Fabrice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2021
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210974/ https://www.ncbi.nlm.nih.gov/pubmed/33780274 http://dx.doi.org/10.1200/JCO.20.01139

Ejemplares similares

PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials
por: Fillbrunn, Mirko, et al.
Publicado: (2022)

Effectiveness of Alpelisib + Fulvestrant Compared with Real‐World Standard Treatment Among Patients with HR+, HER2–, PIK3CA‐Mutated Breast Cancer
por: Turner, Stuart, et al.
Publicado: (2021)

Palbociclib as an early-line treatment for Japanese patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: a review of clinical trial and real-world data
por: Masuda, Norikazu, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Overall Survival with Palbociclib and Fulvestrant in Women with HR(+)/HER2(−) ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
por: Cristofanilli, Massimo, et al.
Publicado: (2022)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
por: Ettl, Johannes, et al.
Publicado: (2020)

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
por: Neven, Patrick, et al.
Publicado: (2021)

Response of Brain Metastases From PIK3CA-Mutant Breast Cancer to Alpelisib
por: Batalini, Felipe, et al.
Publicado: (2020)

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
por: Masuda, Norikazu, et al.
Publicado: (2020)

Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients
por: Masuda, Norikazu, et al.
Publicado: (2018)

Androgen receptor gene expression in primary breast cancer
por: Vidula, Neelima, et al.
Publicado: (2019)

Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2021)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Biology and Targetability of the Extended Spectrum of PIK3CA Mutations Detected in Breast Carcinoma
por: Rugo, Hope S., et al.
Publicado: (2023)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer
por: Iwata, Hiroji, et al.
Publicado: (2013)

Palbociclib in combination with letrozole in patients with estrogen receptor–positive, human epidermal growth factor receptor 2–negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients
por: Mukai, Hirofumi, et al.
Publicado: (2018)

Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy
por: Iwata, Hiroji, et al.
Publicado: (2023)

The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
por: Palli, Swetha Rao, et al.
Publicado: (2015)

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients
por: Iwata, Hiroji, et al.
Publicado: (2017)

Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
por: Inoue, Kenichi, et al.
Publicado: (2021)

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
por: Tolaney, Sara M., et al.
Publicado: (2023)

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2013)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer
por: Loi, Sherene, et al.
Publicado: (2019)

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
por: Iwata, Hiroji, et al.
Publicado: (2013)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
por: Kuroi, Katsumasa, et al.
Publicado: (2014)

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

A risk-based subgroup analysis of the effect of adjuvant S-1 in estrogen receptor-positive, HER2-negative early breast cancer
por: Takada, Masahiro, et al.
Publicado: (2023)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

PIK3CA Mutations in Hepatocellular Carcinoma in Korea
por: Kim, Heesue, et al.
Publicado: (2013)

Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013)

Mutation of the PIK3CA oncogene in human cancers
por: Karakas, B, et al.
Publicado: (2006)

Helical and kinase domain mutations of PIK3CA, and their association with hormone receptor expression in breast cancer
por: Vatte, Chittibabu, et al.
Publicado: (2019)

PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come
por: De Mattos-Arruda, Leticia
Publicado: (2020)

The Capsicum annuum class IV chitinase ChitIV interacts with receptor-like cytoplasmic protein kinase PIK1 to accelerate PIK1-triggered cell death and defence responses
por: Kim, Dae Sung, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_6les280hhi8gehk2etcvdqetmk